

The Era of Personalized IVF International ART Forum

[個人化試管嬰兒時代]國際生殖趨勢論壇





Moderator / 座長

The webinar will open online at 08:30 (UTC+8).

08:30 開放線上入場

09:00-09:05 Opening

Dr. Chii-Ruey Tzeng / 曾啟瑞 醫師

Founder & CEO, Taipei Fertility Center / 臺北婦產科診所生殖中心創辦人兼執行長 Honorary Professor, Taipei Medical University / 臺北醫學大學榮譽教授

Taipei Fertility Center, Taiwan / TFC 臺北婦產科診所 生殖中心









This forum will discuss the research and application of personalized reproductive medicine from the perspective of precision medicine. A total of 8 physicians and experts from 5 countries are invited to share their clinical experience and academic viewpoints, and to bring new light to reproductive medicine.

The development of Pre-implantation Genetic Testing for Aneuploidy (PGT-A) has helped many infertility patients to successfully conceive. However, there are still many management consideration and pondering points after this test. For example, what is the next step after implantation of mosaic embryos? Is it still

possible for the fetus to have uniparental disomy (UPD) or microdeletions? Should Non-Invasive Prenatal Testing (NIPT) or amniotic fluid microarray be considered even after PGT-A? Which one?

MicroRNA has been the up-and-coming new trend in test development encompassing much hope and potential. Its research and application in the field of reproductive medicine is booming and maturing. In particular, the advantages of utilizing microRNA in endometrial receptivity analysis for clinical management is emerging. Speakers in this session will cover diverse aspects surrounding microRNA, including academic research, clinical experience, and future development.

We sincerely invite you to join in this grand event!

本論壇從精準醫療角度來探討個人化生殖醫療研究和應用,集結5個國家共8位醫師與專家學者,從臨床經驗及學術觀點分享如何為生殖醫學帶來新展望。

胚胎著床前染色體檢測(PGT-A)發展幫助許多不孕症患者成功懷孕,但檢測後是否讓醫師仍有疑慮,好比說鑲嵌胚胎植入後的下一步?是否仍可能發生單親二體症或微小片段異常?產檢該用非侵入性染色體檢測(NIPT)或羊水晶片排除潛在風險?

MicroRNA已被視為檢測發展趨勢,在生殖領域研究亦日漸成熟,其中子宮內膜容受性檢測在臨床應用優勢越加浮現,講者分享包含學術探討、臨床結果追蹤及未來發展性。

誠摯邀請各位先進一同共襄盛舉!



REGISTER

線上報名

SESSION 1 - The importance in PGT-A follow up test



09:05-09:20 Dr. Raman Subramaniam Consultant Obstetrician and Gynaecologist

PGT-A its limitations and follow up testing recommendations PGT-A的局限性及後續追蹤檢測建議

來自馬來西亞資深婦產專科醫師的臨床觀點分享

Fetal Medicine & Gynaecology Centre and Pantai Hospital, Malaysia



09:20-09:35 Dr. Fan Chang / 張帆 醫師 President of Fertility Society ,ROC / 中華民國生育醫學會第14屆理事長

Clinical aspect in optimization of healthy IVF live birth: From corrected folliculogenesis to PGTA and SNP array prenatal testing

利用人工生殖科技生下健康寶寶最佳化方式:

從濾泡生成調整到胚胎著床前診斷及SNP晶片羊水檢查

Chang's Fertility Center, Taiwan / 張帆婦產科診所



09:35-09:50 Michael Richardson, PhD
Business Development, APJ

The use of Chromosomal Microarray for Prenatal Testing after IVF

染色體晶片在試管嬰兒後的產前檢測之應用

Reproductive Health, Thermo Fisher Scientific, Singapore



09:50-10:05 Anya Huang, MS, CGC / 黃品嘉 U.S. & Taiwan Certified Genetic Counselor / 遺傳諮詢師

Genetic Counseling for Pre-conception and Prenatal Chromosomal Testing

孕前與產前染色體檢測的遺傳諮詢

GGA Corporation, Taiwan



10:05-10:20 Panel discussion

SESSION 2 - MicroRNA for optimal implantation and clinical case sharing



10:25-10:40 Prof. Dr. Budi Wiweko Sp.OG, K-FER MPH

MicroRNA for optimal implantation and clinical case study

MicroRNA用於理想植入時機及相關臨床案例研究來自2020 ASPIRE主席/印尼學者的分享

Medical Science IMER FMUI & The Committee on Professor Research Council FMUI, Indonesia



10:40-10:55 Dr. Wen-Jui Yang / 楊文瑞 醫師 M.D., Ph.D. / 生殖醫學主任 / 醫學博士

The Role of microRNAs in Endometrial Receptivity and Repeat implantation failure

miRNA在子宮內膜容受性與反覆性胚胎著床失敗中扮演的角色與作用

Taiwan IVF Group, Taiwan / 艾微芙國際生殖醫學中心



10:55-11:10 Dr. Liza Ling Ping
Consultant Obstetrician and Gynaecologist

Clinical aspects in miRNA application for IVF optimization

MicroRNA應用於試管嬰兒療程優化之臨床觀點來自馬來西亞資深IVF醫師的臨床經驗分享

TMC Fertility & Women's Specialist Centre, Malaysia



11:10-11:25 Dr. Xiao-Wei Ji / 季曉微 醫師 Obstetrician and Gynecologist / 生殖中心、婦產科主治醫師

Embryo transfer strategy for RIF patients 反覆性著床失敗個案的胚胎植入策略

Zhongshan Hospital Fudan University, China / 復旦大學附屬中山醫院

